Gastrointestinal stromal tumour

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
4 Unique sponsors
5 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
V Various (ATC V) 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 2 substances
Radiopharmaceutical 1 substance
Phase III: 2 Phase I/II: 1 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Deciphera Pharmaceuticals Inc. Commercial
    RIPRETINIB; SUNITINIB
    2022-503058-37-00 8 countries 2023 n=30 Orphan
    Recruiting
  • Deciphera Pharmaceuticals Inc. Commercial
    RIPRETINIB; SUNITINIB
    2024-513277-52-00 5 countries 2019 n=144 Orphan
    Ended

Phase I/II

1 trial
  • Idrx Inc. Commercial
    [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL] (6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A] PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    2024-514930-19-00 6 countries 2022 n=130 Orphan
    Ended

Phase I (Other)

2 trials
  • Deciphera Pharmaceuticals Inc. Commercial
    IMP not specified
    2022-501477-40-00 3 countries 2024 n=22
    Ended
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-512831-66-00 3 countries 2025 n=16 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Ningbo Newbay Technology Development Co. Ltd. Commercial
    IMP not specified
    2022-502401-15-00 2 countries 2023 n=37
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Deciphera Pharmaceuticals Inc. Commercial 3 Phase I (Other), Phase III 1
ITM Solucin GmbH Commercial 1 Phase I (Other) 1
Ningbo Newbay Technology Development Co. Ltd. Commercial 1 Phase I (First in Human) 0
Idrx Inc. Commercial 1 Phase I/II 0
New trials by year
2019
1
2022
1
2023
2
2024
1
2025
1
← All indication landscapes